References
- Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA303(3), 235–241 (2010).
- Guelinckx I, Devlieger R, Beckers K, Vansant G. Maternal obesity: pregnancy complications, gestational weight gain and nutrition. Obes. Rev.9(2), 140–150 (2008).
- Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat.23(29), 1–44 (2010).
- Lopez LM, Grimes DA, Chen-Mok M, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst. Rev.7, CD008452 (2010).
- Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am. J. Epidemiol.166(11), 1306–1311 (2007).
- Vahratian A, Barber JS, Lawrence JM, Kim C. Family-planning practices among women with diabetes and overweight and obese women in the 2002 National Survey for Family Growth. Diabet. Care32(6), 1026–1031 (2009).
- Kaneshiro B, Edelman A, Carlson N, Nichols M, Jensen J. The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth. Contraception77(4), 234–238 (2008).
- Higginbotham S. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091. Contraception80(6), 583–590 (2009).
- Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet. Gynecol.105(1), 46–52 (2005).
- Grimes DA, Shields WC. Family planning for obese women: challenges and opportunities. Contraception72(1), 1–4 (2005).
- Trussell J. Contraceptive failure in the United States. Contraception83(5), 397–404 (2011).
- Edelman AB, Carlson NE, Cherala G et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity. Contraception80(2), 119–127 (2009).
- Westhoff CL. Impact of body weight on observed pregnancy rates with a low-dose estrogen, 91-day extended regimen oral contraceptive. Contraception80, 196 (2009).
- Hurwitz BE, Henry N, Goldberg RB. Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 1999–2004. Gynecol. Endocrinol.25(7), 441–449 (2009).
- Segall-Gutierrez P, Kjos S. Contraception for the woman with diabetes. In: A Practical Manual of Diabetes in Pregnancy. McCance DR, Maresh M, Sacks DA (Eds). Blackwell Pub., Chichester, UK (2010).
- ACOG Committee on Practice Bulletins – Gynecology. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet. Gynecol.114(4), 936–949 (2009).
- US Medical eligibility criteria for contraceptive use, 2010. MMWR Recomm. Rep.59(RR-4), 1–86 (2010).
- Segall-Gutierrez P, Taylor D, Liu X, Stanzcyk F, Azen S, Mishell DR Jr. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception81(6), 487–495 (2010).
Websites
- Faculty of Family Planning and Reproductive Health Care, Royal College of Obstetricians and Gynecologists. UK medical eligibility criteria for contraceptive use, 2009. London: Faculty of Family Planning and Reproductive Health Care 2009 www.fsrh.org/pdfs/UKMEC2009.pdf (Accessed 23 August 2011)
- Segall-Gutierrez P, Xiang A, Watanabe R et al. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception (June 2011) www.contraceptionjournal.org/article/S0010-7824(11)00181-8/abstract (Accessed 23 August 2011)